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K e y  M e s s a g e s 
1. Overall baseline interferon gamma release assay 
positivity was 20.7%.
2. The conversion to interferon gamma release assay 
positivity at 3 months was 8.85% in the exposed 
group and 4.54% in the non-exposed group using 
the conventional cut-off of 0.35 IU/mL.
3. When grey zone results (0.2I-0.7 IU/mL) 
were included, the proportion of non-specific 
conversions and reversions could be reduced. 
4.  Interferon gamma release assay can be an adjunct 
tool in contact investigation of latent tuberculosis 
infection in healthcare workers.
use of interferon gamma release assay to assess 
latent tuberculosis infection among healthcare 
workers in Hong Kong
DNC Tsang *, CKC Lai, WC Yam, JWM Chan, YW Mok, WH Seto, SC Fung, CM Chu, BHS Lam, TK Ng
Introduction
Tuberculosis (TB) is a highly infectious airborne 
disease. Healthcare workers are at increased risk 
of contracting infection because of exposure to a 
concentration of infectious patients in their work 
environment. Contact investigations are hampered 
by the lack of specific markers. The tuberculin 
skin test (TST) has been used to diagnose latent 
tuberculosis infection (LTBI) with variable success, 
as the majority of local residents have been 
inoculated with Bacillus Calmette-Guérin (BCG) 
vaccine at birth.1 
 In-vitro interferon gamma release assay 
(IGRA) including QuantiFERON-TB Gold In-Tube 
(QFT-GIT) can identify individuals infected with 
TB who have been vaccinated with BCG. It is non-
invasive, with no ‘booster’ effect from repeated 
testing, and less painful compared with TST. 
Nonetheless, its applicability to daily use including 
contact investigation remains unclear, owing to the 
complex biological basis of IGRA. 
methods
This was a prospective cohort study. Healthcare 
workers from three acute hospitals with or without 
unprotected exposure to smear-positive TB patients 
were recruited between 1 January 2010 and 30 June 
2011 and followed up until 30 June 2012 using QFT-
GIT, as per the manufacturer’s recommendations.2 
The two groups were matched for sex, age, rank, 
and department. Outcome measures included the 
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baseline positive rate, the conversion and reversion 
over time, and the associated factors.
 The number of years as a healthcare worker 
and the exposure incident including nature and 
duration were recorded. Blood samples were taken 
at baseline, 3 months, 6 months, and 12 months. Any 
participants with ambiguous QFT-GIT results or 
symptoms suggestive of active TB were encouraged 
to seek medical advice from microbiologists of 
the investigation team. They were then referred to 
respiratory physicians for further assessment using 
sputum AFB smear, culture, and chest radiography. 
Results
A total of 159 exposed and 120 non-exposed 
healthcare workers aged 22 to 63 (mean, 39.2) years 
were recruited. The mean number of years as a 
healthcare worker was 11.48 (range, 0.1-43) years. 
The female-to-male ratio was 82.4:17.6; 59.5% of 
participants were nurses. Participants were recruited 
from non-admission medical wards (26.2%), medical 
admission wards (23.3%), orthopaedic wards 
(24.4%), surgical wards (13.3%), and others (12.9%). 
Baseline characteristics of the two groups were 
comparable. A total of 46 TB contact investigations 
were performed.
 The baseline QFT-GIT positivity for the 
exposed and non-exposed groups was 19.5% and 
20.8%, respectively (relative risk [RR]=0.96, 95% 
CI=0.74-1.25, P>0.05). It was associated with age 
≥40 years (RR=1.62, 95% CI=1.23-2.11), and working 
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as a healthcare worker for ≥10 years (RR=1.44, 95% 
CI=1.15-1.79). Department or staff type was not 
associated with baseline positivity.
 Regarding conversion and reversion over time, 
the AFB smear positivity of the index patients was 
as follows: AFB + 34.5%, ++ 12.8%, and +++ 52.7%. 
The mean number of hours of exposure was 27.08 
(range, 8-220). Using a conventional cut-off of 0.35 
IU/mL, 142 and 113 subjects from the exposed and 
non-exposed group had >1 specimen for assessment 
of conversion or reversion, respectively. For the 
respective groups, conversion at 3 months was 
8.85% (10/113) and 4.54% (4/88) (RR=1.30, 95% 
CI=0.91-1.85), whereas conversion was detected 
in 14.2% (16/113) and 13.6% (12/88), and reversion 
occurred in 25% (7/28) and 29.2% (7/24). When a 
grey zone of 0.2 to 0.7 IU/mL was implemented, 133 
and 106 participants in the respective groups were 
eligible for analysis: conversion at 3 months was 
2.97% (3/101) and 1.03% (1/79), whereas conversion 
during the study period was 4.95% (5/101) and 3.79% 
(3/79), and reversion occurred in 13.6% (3/22) and 
0% (0/13).
 Eight participants asked about their 
QFT-GIT results; two of them had sputum and 
chest radiographs examined and all were negative. 
No participant required consultation with a chest 
physician. One participant from the non-exposed 
group developed active TB. The three blood results 
were all >1 IU/ml. No participant from the exposed 
group had active TB. 
Discussion
Conversion to positivity at 3 months was adequate 
to determine the infection status of contacts. The 
3-month period is also the time frame required to 
exclude a false negative TST result following TB 
exposure.3 
 The overall baseline positivity rate was 20.7% 
using the conventional cut-off point. The exact 
significance of QFT-GIT positivity is not clearly 
understood. Although it is mostly implicated as 
diagnostic for LTBI, it can also represent a state of 
active TB infection, or even treated TB infection. 
QFT-GIT has consistently shown a higher specificity 
than TST, especially in BCG-vaccinated populations. 
 Conversion is generally interpreted as the 
acquisition of TB infection after a definitive history 
of TB exposure. False conversion can be due to 
TABLE 1.  Participant characteristics*
Characteristics Overall (n=279) Exposed (n=159) Non-exposed (n=120) P value (exposed vs 
non-exposed)
Age (years) 39.20±10.68 (63-22) 39.79±10.64 (58-22) 38.41±10.73 (63-22) >0.05
No. of years as a healthcare worker 11.48±9.12 (43-0.1) 11.43±9.10 (37-0.1) 11.56±9.19 (43-0.5) >0.05
Age-group (years) >0.05
<30 62 (22.7) 34 (21.8) 28 (23.9)
30-39 93 (34.1) 48 (30.8) 45 (38.5)
40-49 55 (20.1) 35 (22.4) 20 (17.1)
≥50 63 (23.1) 39 (25.0) 24 (20.5)
No. of years as a healthcare worker >0.05
<10 122 (46.2) 70 (47.3) 52 (44.8)
≥10 142 (53.8) 78 (52.7) 64 (55.2)
Sex >0.05
Female 230 (82.4) 134 (84.3) 96 (80.0)
Male 49 (17.6) 25 (15.7) 24 (20.0)
Ward/department <0.05
Medical 73 (26.2) 42 (26.4) 31 (25.8)
Medical admission 65 (23.3) 44 (27.7) 21 (17.5)
Orthopaedics 68 (24.4) 15 (9.4) 53 (44.2)
Surgical 37 (13.3) 33 (20.8) 4 (3.3)
Others 36 (12.9) 25 (15.7) 11 (9.2)
Staff type >0.05
Nursing 166 (59.5) 95 (59.7) 71 (59.2)
Allied health, supporting, and others 113 (40.5) 64 (40.3) 49 (40.8)
* Data are presented as mean±SD (range) or No. (%) of participants
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concomitant illness, non-specific boosting, and 
fluctuation of IFN-gamma responses, as well as 
laboratory factors. When analysing risk factors for 
conversion at 3 months for the exposed group, age 
≥40 was a significant risk (RR=1.96, 95% CI=1.30-
2.96), raising the possibility of an immune-boosting 
phenomenon. No relationship between conversion 
and TB disease was identified; thus longer follow-
* Three indeterminate results (one from exposed and two from non-exposed group)
TABLE 2.  QuantiFERON-TB Gold In-Tube (QFT-GIT) test results
QFT-GIT test No. (%) of participants Relative risk 
(95% CI)





Positive 56 (20.1) 31 (19.5) 25 (20.8)
Negative or indeterminate* 223 (79.9) 128 (80.5) 95 (79.2)
Conversion to positivity in the 2nd blood sample 1.30 (0.91-1.85)
Yes 14 (6.9) 10 (8.8) 4 (4.5)
No 189 (93.1) 104 (91.2) 85 (95.5)
TABLE 3.  Association between participant characteristics, exposure details, and baseline positivity









Exposure >0.05 0.96 (0.74-1.25)
Non-exposed (reference) 25 (20.8) 95 (79.2)
Exposed 31 (19.5) 128 (80.5)
AFB result of the index patient >0.05 -
Non-exposed 25 (20.8) 95 (79.2)
+ 7 (13.7) 44 (86.3)
++ 4 (21.1) 15 (78.9)
+++ 17 (21.8) 61 (78.2)
Age (years) <0.05 1.62 (1.23-2.11)
<40 (reference) 20 (12.9) 135 (87.1)
≥40 33 (28.0) 85 (72.0)
No. of years as healthcare worker <0.05 1.44 (1.15-1.79)
<10 (reference) 15 (12.3) 107 (87.7)
≥10 37 (26.1) 105 (73.9)
Sex >0.05 0.78 (0.39-1.56)
Female (reference) 48 (20.9) 182 (79.1)
Male 8 (16.3) 41 (83.7)
Ward/department >0.05 -
Medical 14 (19.2) 59 (80.8)
Medical admission 13 (20.0) 52 (80.0)
Orthopaedics 13 (19.1) 55 (80.9)
Surgical 6 (16.2) 31 (83.8)
Others 10 (27.8) 26 (72.2)
Staff type >0.05 1.07 (0.76-1.51)
Nursing (reference) 32 (19.3) 134 (80.7)
Allied Health, supporting and others 24 (21.2) 89 (78.8)
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up is required. Reversion may be due to a ‘false 
positive’ in the first specimen, or spontaneous 
immune clearing of the infection with TB treatment. 
‘Wobbling phenomenon’ may be due to one or more 
factors mentioned above. In one longitudinal study, 
contacts with precisely defined exposure in point-
source outbreaks were monitored serially. Subjects 
who had transiently positive IGRA results were 
identified; there was a possibility that some contacts 
may have acquired, and spontaneously cleared, a 
transient M tuberculosis infection.4 Nonetheless, 
an immune-boosting phenomenon is a more likely 
explanation. In the present study, transient change 
of positivity/negativity was noted in 16 participants.
 Non-specific conversion and reversion is a cause 
of concern, as this might precipitate unnecessary 
LTBI treatment. Participants with results close to the 
cut-off value of 0.35 IU/mL tended to have more non-
specific conversions and reversions. A high positive 
result of >1.0 IU/mL tended to remain positive. For 
this reason, a grey zone of 0.2-0.7 IU/mL is proposed. 
Results outside this zone are presumed to be true 
negatives or positives. In the present study, the use 
of a grey zone significantly reduced the number of 
conversions and reversions. Whether this reduction 
represents a true improvement in detection of true 
conversion and reversion has yet to be confirmed. In 
addition, the current FDA-approved package insert 
and management guidelines do not provide advice 
on interpretation of results in the grey zone.5 
 As the high positive result of >1.0 IU/mL tends 
to remain positive, quantitative measurements for 
IGRAs should be reported.3 This may be highly 
relevant as the only participant that developed 
active TB disease had high values (>1 IU/mL). 
Nonetheless, there are no interpretive guidelines 
for the quantitative levels. The following approach 
to interpretation has been recommended: (1) 
quantitative results should not be used for prognostic 
or therapeutic monitoring purposes at this time, 
and (2) if the quantitative results are close to cut-off 
values, reversion or conversion is more likely upon 
re-testing.5
 The most appropriate contact investigation 
procedure in Hong Kong hospitals remains 
controversial. In our study, the baseline LTBI rate was 
quantified as 20.7%. For IGRA, the exposed group had 
a tendency to convert at 3 months, regardless of the 
cut-off value, indicating an association between TB 
exposure and conversion. Despite the large cohort, 
none of the exposure events reached the threshold 
of AFB +++ with exposure ≥120 hours arbitrarily set 
by the infection control team of the Queen Elizabeth 
Hospital. Repeated immune boosting might be a 
significant cause of QFT-GIT positivity, as evidenced 
by the association of baseline positivity with age ≥40 
years and working as a healthcare worker for ≥10 
years, as well as more conversion with age ≥40 years. 
No clear association between QFT-GIT positivity 
and active TB disease was found, possibly owing to 
the short follow-up duration of one year. 
 Further studies to include longer term serial 
monitoring, other TB exposure events, and the 
prognostic implication of IGRA in the development 
of active TB disease are warranted.
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